Metastatic Renal Cell Cancer
Conditions
Brief summary
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Interventions
Undergo perfusion CT
Sponsors
Siemens Healthcare QT
Stanford University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Suspected or biopsy-proven renal cell carcinoma * Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent * Ability to understand and willingness to sign a written informed consent document
Exclusion criteria
* Serum creatinine greater than or equal to 1.7 mg/dL * Severe allergy to contrast agent * Any contraindication for undergoing a CT scan * Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterization of the relationship between Change in blood flow measured through perfusion CT techniques and Change in tumor size measured through non-investigational CT | 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication |
Secondary
| Measure | Time frame |
|---|---|
| Characterization of the relationship between change in perfusion CT measurements (eg. Mean transit time) and change in tumor size measured by non-investigational CT | 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication |
| Relationship between change in blood flow and tumor response measured on ordinal scale | 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication |
| Relationship between change in blood flow at Day 8 and change in tumor size measured on continuous scale at Week 12 and tumor response measured on ordinal scale at Week 12 | 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication |
| Relationship between change in blood flow at Day 8 and at Week 12 and progression-free survival | 12 weeks after start of standard systemic targeted therapy medication |
| Relationship between change in blood flow at Day 8 and at Week 12 and time to nadir of tumor size | 12 weeks after start of standard systemic targeted therapy medication |
Countries
United States
Outcome results
None listed